Dhingra Kapil sold $408K of REPL
Dhingra Kapil sold 21,500 shares of Replimune Group, Inc. (REPL) at $19.00 ($0.41M total) on 2026-11-02.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership, which may be interpreted as reduced confidence, prompting short sellers.
Market read
Primary insider sale filing; modest size but notable for a micro‑cap, offering a low‑actionability trading signal.
What to watch
Potential upcoming clinical data releases or partnership news that could offset the negative signal.
Background
SEC Form 4 filing discloses insider transactions. Directors' sales are monitored for signals about company outlook.
Ticker impact
Director Kapil Dhingra sold 21,500 shares for $408,500, reducing his stake to 21,669 shares.
likely slight downward pressure as the market prices the insider sell
Form 4 is a primary source; a $408k sale by a director is material for a micro‑cap and can trigger short‑term selling.
Market effects
Minimal; the sale is company‑specific and does not affect the broader biotech sector.
None; REPL trades on US exchanges only.
Low; limited to investors tracking REPL.
Counterpoint
The sale could be a routine liquidity event unrelated to fundamentals, so price may remain stable.
Key entities
- CompanyReplimune Group, Inc.
Biotech firm developing oncolytic virus therapies.
- PersonKapil Dhingra
Director of Replimune Group, Inc.


